Crossmark

A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma

Crossref DOI link: https://doi.org/10.1007/s11060-024-04904-y

Published Online: 2025-01-06

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Narsinh, Kazim H.

Kumar, Karishma

Bankiewicz, Krystof

Martin, Alastair J.

Berger, Mitchell

Clarke, Jennifer

Taylor, Jennie

Bush, Nancy Ann Oberheim

Molinaro, Annette M.

Aghi, Manish

Butowski, Nicholas
Funding

Funding for this research was provided by:

National Institutes of Health (5R21CA186140-02)
License Information

Text and Data Mining valid from 2025-01-06

Version of Record valid from 2025-01-06
More Information

Article History

Received: 4 February 2024

Accepted: 3 December 2024

First Online: 6 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below